Portuguese 
English 
Spanish 
5 min of reading 
0 comments 
New study conducted by US scientists points to promising path in combating Alzheimer’s, with advance that may improve memory and open new solution for the disease
Science has taken a significant step in the attempt to reverse memory loss in Alzheimer’s. A study conducted by the Cold Spring Harbor Laboratory and published in PNAS on February 2, 2026, identified an innovative strategy based on the inhibition of the PTP1B protein.
In tests with animal models, the results showed significant improvement in memory and reduction of disease-associated plaques, one of the main challenges in Alzheimer’s treatment.
The research was led by scientist Nicholas Tonks, alongside Yuxin Cen and Steven Ribeiro Alves. The study indicates that acting on multiple disease mechanisms may be the most effective way to tackle a problem that, to date, presents limited responses in medicine.
-
Larger than two football fields, with a swimming pool, sauna, and 20 nuclear missiles, the gigantic Soviet submarine spent up to 120 days hidden under the Arctic ice and became one of the most terrifying monsters of the Cold War.
-
GameStop throws R$ 275 billion on the table to buy eBay and become a competitor to face Amazon head-on. The plan includes transforming 1,600 physical stores into logistics centers, cutting R$ 10 billion in costs in the first year, and using live streams to revolutionize the way the world shops online.
-
The Amazonian pororoca is losing strength; the four-meter giant wave that advanced against the river current hasn’t appeared with intensity since 2020. Deforestation and silting are destroying the balance that created the phenomenon, and scientists warn that it could disappear.
-
Brazil removes 15 million m³ of sediments from the seabed in a colossal R$ 432.2 million dredging operation at the Port of Rio Grande, in a 30 km submerged operation to make way for giant ships.
How protein accumulation affects the brain in Alzheimer’s
Alzheimer’s is characterized by profound changes in the brain, especially by the accumulation of plaques formed by the beta-amyloid (Aβ) protein. This peptide is naturally produced by the body, but in people with the disease, it accumulates abnormally.
These plaques directly interfere with communication between neurons, impairing essential cognitive functions such as memory, reasoning, and learning. Furthermore, they affect the myelin sheath, a structure responsible for protecting and accelerating nerve signals.
Another important point involves microglia, cells responsible for cleaning the brain. Over time, these cells lose efficiency, allowing waste to accumulate. This process is one of the main obstacles to reversing memory loss in Alzheimer’s, as the brain loses its natural defense capacity.
The PTP1B protein and the path to reversing memory loss in Alzheimer’s
Discovered in 1988 by Nicholas Tonks, the PTP1B protein was already known for its role in metabolism. It belongs to the tyrosine phosphatase family, responsible for regulating signals within cells.
This protein acts primarily in processes linked to insulin and leptin, hormones that control blood sugar and body weight. For this reason, it has been studied for decades as a therapeutic target for diseases such as type 2 diabetes and obesity.
In the brain, however, its function goes further. PTP1B also participates in:
- Regulation of synapses
- Control of cerebral immune response
- Processes linked to memory and learning
This multifunctional role caught the attention of researchers, who began to investigate its potential to reverse memory loss in Alzheimer’s.
The experiment with mice and the observed results
In the most recent study, the team led by Tonks analyzed what happens when the PTP1B protein is inhibited. For this, genetically modified mice were used to develop Alzheimer’s.
The results were considered significant. Without the action of PTP1B, the animals showed improvement in learning and memory deficits, as well as a significant reduction in beta-amyloid plaques in the brain.
This advance indicates that it is possible not only to slow down the disease but also to reverse memory loss in Alzheimer’s at certain stages, at least in experimental models.
The role of the SYK protein in brain cleaning
One of the most interesting findings of the research involves the SYK protein, which regulates the activity of microglia. PTP1B acts as a brake on this protein.
When PTP1B is blocked, SYK activity increases, making microglia more efficient at removing beta-amyloid plaques. In practice, this means that the brain recovers part of its cleaning capacity.
This mechanism is considered central to attempting to reverse memory loss in Alzheimer’s, as it acts directly on the origin of the problem, and not just on the symptoms.
Relationship between metabolism, type 2 diabetes, and Alzheimer’s
Another aspect that broadens the study’s relevance is the link between metabolic diseases and Alzheimer’s. PTP1B itself was already being studied as a therapeutic target for type 2 diabetes and obesity.
This connection is no coincidence. Research shows that people with these conditions have a higher risk of developing Alzheimer’s. This occurs because metabolic changes directly affect brain function.
Among the factors contributing to this relationship are:
- Insulin resistance
- Chronic inflammation
- Changes in cellular signaling
- Accumulation of toxic proteins
This interconnection suggests that treating metabolism could be a complementary strategy to reverse memory loss in Alzheimer’s, opening new therapeutic possibilities.
Difference between the new approach and current treatments
Currently, Alzheimer’s treatments primarily focus on reducing beta-amyloid plaques. However, the results are limited, and not all patients show significant improvement.
The PTP1B-based proposal is different because it acts on several fronts simultaneously. Instead of attacking just one aspect of the disease, it influences different biological processes.
Key differentiators include:
- Simultaneous action on multiple mechanisms
- Stimulation of the brain’s immune response
- Impact on metabolic and neuronal functions
- Potential for combined use with other medications
This approach increases the chances of success and could represent a significant advance in the attempt to reverse memory loss in Alzheimer’s.
Next steps and development of new medications
Following promising results in animal models, the next step is to translate this discovery into viable treatments for humans. To this end, researchers are working on developing PTP1B inhibitors.
This stage involves a partnership with the company DepYmed Inc., which is already active in the development of metabolic therapies.
The expectation is that these medications can be combined with existing treatments, enhancing their effects. The ultimate goal is to slow the progression of the disease and improve patients’ quality of life.
Although a definitive cure does not yet exist, advances indicate that science is getting closer to concretely reversing memory loss in Alzheimer’s.
The real-world impact of this discovery by US scientists
Alzheimer’s is one of the most challenging diseases today, affecting millions of people worldwide. Progressive memory loss compromises patient autonomy and creates profound impacts on the family.
an approach capable of reversing memory loss in Alzheimer’s could completely transform this scenario. More than prolonging life, the goal becomes preserving its quality.
Among the main expected benefits are:
- Recovery of cognitive functions
- Greater patient independence
- Reduction of family emotional impact
- Decrease in continuous care costs
These factors show that the impact goes far beyond medicine, reaching social and economic aspects.
A new horizon for Alzheimer’s treatment
The results of the study led by Nicholas Tonks represent a significant advance in understanding Alzheimer’s and its mechanisms. By identifying the PTP1B protein as a therapeutic target, researchers have opened a new path that could change how the disease is treated.
There are still important steps ahead, including clinical trials and human validation. However, current data are consistent enough to generate optimism in the scientific community.
The possibility of reversing memory loss in Alzheimer’s is no longer just a distant hypothesis and is becoming an increasingly plausible goal. This advance reinforces the importance of continuous scientific research and the search for innovative solutions for complex diseases.
If confirmed, this approach could represent one of the greatest transformations ever seen in the treatment of neurodegenerative diseases, bringing real hope to patients, families, and healthcare professionals worldwide.
Be the first to react!